Brief

last 24h

[2/2] 222 sources

Multi-source AI news clustered, deduplicated, and scored 0–100 across authority, cluster strength, headline signal, and time decay.

RESEARCH · 36氪 (36Kr) 中文(ZH) · 3h

3D printing technology for the development of new drugs

Southbound capital saw a net inflow of HK$4.657 billion, with Akeso Bio, Tencent Holdings, and Pop Mart being the top three net buyers. Akeso Bio specifically received a net purchase of HK$2.707 billion. In contrast, Lenovo Group, Xiaomi Group-W, and Kingboard Laminates experienced net sales. AI

IMPACT Significant capital flow into biotech and tech stocks, with Akeso Bio being a major recipient, potentially impacting future R&D and market strategies.
TOOL · SCMP — Tech English(EN) · 3h

Akeso lung cancer drug shines in trials, boosting hopes in US$20b market

Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive after two years compared to 48.6% in the control group. Analysts are optimistic about its potential to transform non-small cell lung cancer therapy and capture a substantial share of the global market, though the company's stock saw a slight dip. AI
- Akeso
- ivonescimab